INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 ...

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...

Emgality (fremanezumab) is a migraine medication prescribed to reduce the number and severity of migraine attacks in adults. Although no single migraine treatment works for everyone, some people have ...

Emgality (galcanezumab-gnlm) and Aimovig (erenumab-aooe) are brand-name drugs prescribed to help prevent migraine episodes. Emgality is also prescribed to treat cluster headache. Both drugs are ...

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...

Eli Lilly’s first effort for migraine drug Emgality had a personal connection for the director of the TV commercial. Robert Stromberg, who has worked on blockbuster movies including “Avatar” and ...